Urol. praxi, 2011; 12(2): 100-104

Advances in targeted biological therapy for renal carcinoma

MUDr.Petra Holečková
Ústav radiační onkologie, FN Na Bulovce a 1. LF UK, Praha

Renal carcinoma is a chemoresistant and radioresistant tumour. The only curative treatment in the early stage of the disease is surgery.

Targeted biological therapy in which receptor tyrosine kinase inhibitors, mTOR inhibitors as well as the VEGF-binding monoclonal antibody

are used has been a major breakthrough in the treatment for metastatic renal carcinoma in the last few years.

against VEGF.

Keywords: renal carcinoma, targeted biological therapy, receptor tyrosine kinase inhibitors, mTOR inhibitors, monoclonal antibody

Published: April 1, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Holečková P. Advances in targeted biological therapy for renal carcinoma. Urol. praxi. 2011;12(2):100-104.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Abeloff MD, et al. Clinical Oncology. 3rd ed. Philadelphia, PA.
    2. Cochrane Database Syst Rev. 2005; (1): CD001425.
    3. Escudier B, Eisen T, Stadler W. Sorafenib in Advanced Renal Cell Carcinoma. N Engl J Med. 2007; 356: 125-134. Go to original source... Go to PubMed...
    4. U. S. Food and Drug Administration (www.accessdata. fda.gov).
    5. Kawaciuk I. Prognóza karcinomu ledviny. 1. vydání. Galén, 2003: 9-12.
    6. Motzer M, Hutson T, Tomczak P. Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma. N Engl. J Med 2007; 536: 115-124. Go to original source... Go to PubMed...
    7. Escudier J, Bellmut N, Nagier S. Final results of the phase III, randomized, double-blind AVOREN trial of first-line bevacizumab (BEV) + interferon-? 2a (IFN) in metastatic renal cell carcinoma (mRCC), Journal of Clinical Oncology, 2009 ASCO Annual Meeting Proceedings (Post-Meeting Edition). 2009; 27(15): 5020. Go to original source...
    8. Motzer M, Escudier B, Oudard S. Efficacy of everolimus in advanced renal cell carcinoma: a double blind, randomised, placebo controled phase III trial, www.thelancet.com, 2008; DOI: 10.1016/S0140-6736 (08)61039-9.
    9. Hudes G, Carducci M, Tomczak P. Temsirolimus, Interferon Alfa, or Both for Advanced Renal Cell Carcinoma. N Engl J Med, 2007; 235: 2271-2281. Go to original source... Go to PubMed...
    10. Strenberg C, Davis I, Mardiak J. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. Journal of Clinical Oncology, 2010; 28(6): 1061-1068. Go to original source... Go to PubMed...
    11. Vyzula R, a kol. Zásady cytostatické léčby maligních onkologických onemocnění. 2011; ČLS JEP, 12. vydání: 75-82.
    12. http://www.uroweb.org/guidelines/
    13. Escudier B, Kataja V. On behalf of the ESMO Guidelines Working Group, Renal cell carcinoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Anals of Oncology, 2009; 20(suppl. 4): 81-82. Go to original source... Go to PubMed...

    Return to the content


    Urology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.